• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚洲炎症性肠病患者的感染并发症:第八届亚洲克罗恩病和结肠炎组织会议上一项基于网络的多国调查结果

Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.

作者信息

Jun Yu Kyung, Koh Seong-Joon, Myung Dae Seong, Park Sang Hyoung, Ooi Choon Jin, Sood Ajit, Im Jong Pil

机构信息

Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Division of Gastroenterology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

出版信息

Intest Res. 2023 Jul;21(3):353-362. doi: 10.5217/ir.2023.00013. Epub 2023 Jul 27.

DOI:10.5217/ir.2023.00013
PMID:37533266
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10397552/
Abstract

BACKGROUND/AIMS: Infectious complications are major concerns when treating patients with inflammatory bowel disease (IBD). This study evaluated clinical differences across countries/regions in the management of infectious diseases in patients with IBD.

METHODS

A multinational online questionnaire survey was administered to participants at the 8th meeting of the Asian Organization for Crohn's and Colitis. The questionnaire included questions regarding surveillance, diagnosis, management, and prevention of infection in patients with IBD.

RESULTS

A total of 384 physicians responded to the questionnaire. The majority of Korean (n=70, 63.6%) and Chinese (n=51, 51.5%) physicians preferred vancomycin to metronidazole in the treatment of Clostridium difficile infection, whereas more than half of the Japanese physicians (n=62, 66.7%) preferred metronidazole. Physicians in Korea (n=88, 80.0%) and China (n=46, 46.5%) preferred a 3-month course of isoniazid and rifampin to treat latent tuberculosis infection, whereas most physicians in Japan (n=71, 76.3%) favored a 9-month course of isoniazid. Most Korean physicians (n=89, 80.9%) recommended hepatitis B virus (HBV) vaccination in patients lacking HBV surface antigen, whereas more than half of Japanese physicians (n=53, 57.0%) did not consider vaccination.

CONCLUSIONS

Differences in the diagnosis, prevention, and management of infections in patients with IBD across countries/regions reflect different prevalence rates of infectious diseases. This survey may broaden understanding of the real-world clinical settings across Asian countries/regions and provide information for establishing practical guidelines to manage patients with IBD.

摘要

背景/目的:在治疗炎症性肠病(IBD)患者时,感染性并发症是主要关注点。本研究评估了不同国家/地区在IBD患者感染性疾病管理方面的临床差异。

方法

在亚洲克罗恩病和结肠炎组织第8次会议上,对参与者进行了一项跨国在线问卷调查。问卷包括有关IBD患者感染监测、诊断、管理和预防的问题。

结果

共有384名医生回复了问卷。在治疗艰难梭菌感染时,大多数韩国医生(n = 70,63.6%)和中国医生(n = 51,51.5%)更倾向于使用万古霉素而非甲硝唑,而超过一半的日本医生(n = 62,66.7%)更倾向于使用甲硝唑。韩国医生(n = 88,80.0%)和中国医生(n = 46,46.5%)更倾向于使用异烟肼和利福平3个月疗程来治疗潜伏性结核感染,而大多数日本医生(n = 71,76.3%)则倾向于使用异烟肼9个月疗程。大多数韩国医生(n = 89,80.9%)建议对缺乏乙肝表面抗原的患者进行乙肝病毒(HBV)疫苗接种,而超过一半的日本医生(n = 53,57.0%)不考虑接种疫苗。

结论

不同国家/地区IBD患者感染的诊断、预防和管理差异反映了传染病的不同流行率。这项调查可能会拓宽对亚洲国家/地区实际临床情况的理解,并为制定IBD患者管理的实用指南提供信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3865/10397552/cc016d8a13c7/ir-2023-00013f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3865/10397552/6e0dc7ae3519/ir-2023-00013f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3865/10397552/0a6a9c9e01e5/ir-2023-00013f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3865/10397552/6f2959daca1b/ir-2023-00013f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3865/10397552/cc016d8a13c7/ir-2023-00013f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3865/10397552/6e0dc7ae3519/ir-2023-00013f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3865/10397552/0a6a9c9e01e5/ir-2023-00013f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3865/10397552/6f2959daca1b/ir-2023-00013f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3865/10397552/cc016d8a13c7/ir-2023-00013f4.jpg

相似文献

1
Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.亚洲炎症性肠病患者的感染并发症:第八届亚洲克罗恩病和结肠炎组织会议上一项基于网络的多国调查结果
Intest Res. 2023 Jul;21(3):353-362. doi: 10.5217/ir.2023.00013. Epub 2023 Jul 27.
2
Diagnosis of inflammatory bowel disease-Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.炎症性肠病的诊断——亚洲视角:第八届亚洲克罗恩病和结肠炎组织会议基于网络的多国调查结果
Intest Res. 2023 Jul;21(3):328-338. doi: 10.5217/ir.2023.00012. Epub 2023 Jul 27.
3
Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul.亚洲炎症性肠病的诊断:在首尔举行的第二届亚洲克罗恩病和结肠炎组织(AOCC)会议上进行的一项跨国网络调查结果
Intest Res. 2016 Jul;14(3):224-30. doi: 10.5217/ir.2016.14.3.224. Epub 2016 Jun 27.
4
Vaccination in patients with inflammatory bowel disease-Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.炎症性肠病患者的疫苗接种——亚洲视角:第八届亚洲克罗恩病和结肠炎组织会议上一项基于网络的多国调查结果
Intest Res. 2023 Jul;21(3):363-374. doi: 10.5217/ir.2023.00015. Epub 2023 Jun 16.
5
Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul.亚洲炎症性肠病的治疗:在首尔举行的第二届亚洲克罗恩病和结肠炎组织(AOCC)会议上进行的一项基于网络的多国调查结果
Intest Res. 2016 Jul;14(3):231-9. doi: 10.5217/ir.2016.14.3.231. Epub 2016 Jun 27.
6
Treatment of inflammatory bowel disease-Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.炎症性肠病的治疗——亚洲视角:第八届亚洲克罗恩病和结肠炎组织会议上一项基于网络的多国调查结果
Intest Res. 2023 Jul;21(3):339-352. doi: 10.5217/ir.2022.00135. Epub 2023 Jul 27.
7
A questionnaire-based survey on the diagnosis and management of inflammatory bowel disease in East Asian countries in 2012.2012 年东亚国家炎症性肠病诊断和治疗的问卷调查。
Digestion. 2014;89(1):88-103. doi: 10.1159/000356706. Epub 2014 Jan 20.
8
Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study.亚洲炎症性肠病患者机会性感染的现状:一项基于问卷的多中心研究。
Gut Liver. 2022 Sep 15;16(5):726-735. doi: 10.5009/gnl210217. Epub 2022 May 25.
9
Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia.炎症性肠病的药物治疗与监测:一项在亚洲开展的多国问卷调查研究
Intest Res. 2022 Apr;20(2):213-223. doi: 10.5217/ir.2021.00031. Epub 2022 Apr 29.
10
Quality of care in inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul.亚洲炎症性肠病的医疗质量:在首尔举行的第二届亚洲克罗恩病和结肠炎组织(AOCC)会议上进行的一项跨国网络调查结果
Intest Res. 2016 Jul;14(3):240-7. doi: 10.5217/ir.2016.14.3.240. Epub 2016 Jun 27.

引用本文的文献

1
Assessing tuberculosis risk in Crohn's disease patients receiving biologic therapies: real-world insights from Japan.评估接受生物疗法的克罗恩病患者的结核病风险:来自日本的真实世界见解。
Intest Res. 2025 Jul;23(3):231-232. doi: 10.5217/ir.2025.00117. Epub 2025 Jul 29.
2
Guselkumab in East Asians With Moderate-to-Severe Ulcerative Colitis: Subgroup Analysis of the QUASAR Induction and Maintenance Studies.古塞库单抗治疗东亚中重度溃疡性结肠炎:QUASAR诱导和维持研究的亚组分析
J Gastroenterol Hepatol. 2025 Sep;40(9):2197-2208. doi: 10.1111/jgh.17036. Epub 2025 Jun 26.
3
Evolution of inflammatory bowel disease in Korea: a 60-year perspective on clinical and research development.

本文引用的文献

1
Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis.炎症性肠病患者中乙型肝炎病毒和丙型肝炎病毒感染的患病率:一项系统评价和荟萃分析。
Intest Res. 2023 Jul;21(3):392-405. doi: 10.5217/ir.2022.00094. Epub 2022 Dec 2.
2
Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease.接受抗肿瘤坏死因子α制剂治疗的炎症性肠病患者的乙型肝炎病毒抗病毒预防
Gut Liver. 2022 Jul 15;16(4):501-502. doi: 10.5009/gnl220186.
3
Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU.
韩国炎症性肠病的演变:临床与研究发展的60年视角
Intest Res. 2025 Jul;23(3):233-253. doi: 10.5217/ir.2025.00073. Epub 2025 Jun 23.
4
Characteristics and outcomes of portal vein thrombosis in patients with inflammatory bowel disease in Korea.韩国炎症性肠病患者门静脉血栓形成的特征及转归
Korean J Intern Med. 2025 Mar;40(2):243-250. doi: 10.3904/kjim.2024.181. Epub 2024 Dec 23.
5
Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study.韩国溃疡性结肠炎患者对粪便微生物群移植的认知:一项 KASID 多中心研究。
Korean J Intern Med. 2024 Sep;39(5):783-792. doi: 10.3904/kjim.2024.053. Epub 2024 Aug 30.
6
The Burden of Infection in Korea.韩国的感染负担。
J Korean Med Sci. 2024 Apr 1;39(12):e122. doi: 10.3346/jkms.2024.39.e122.
7
Diagnosis, management, and prevention of infectious complications in inflammatory bowel disease: variations among Asian countries.炎症性肠病感染性并发症的诊断、管理及预防:亚洲国家间的差异
Intest Res. 2023 Jul;21(3):277-279. doi: 10.5217/ir.2023.00076. Epub 2023 Jul 27.
炎症性肠病患者潜伏性结核感染筛查策略的表现:来自GETECCU的ENEIDA注册研究结果
J Clin Med. 2022 Jul 5;11(13):3915. doi: 10.3390/jcm11133915.
4
Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study.亚洲炎症性肠病患者机会性感染的现状:一项基于问卷的多中心研究。
Gut Liver. 2022 Sep 15;16(5):726-735. doi: 10.5009/gnl210217. Epub 2022 May 25.
5
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?亚洲炎症性肠病流行病学的最新情况:我们目前处于什么阶段?
Intest Res. 2022 Apr;20(2):159-164. doi: 10.5217/ir.2021.00115. Epub 2022 Apr 29.
6
Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease.抗肿瘤坏死因子α治疗炎症性肠病患者乙型肝炎病毒感染的临床过程。
Gut Liver. 2022 May 15;16(3):396-403. doi: 10.5009/gnl210081.
7
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation.接受不同生物制剂的炎症性肠病患者不良事件的发生率比较:回顾性长期评估
Intest Res. 2022 Jan;20(1):114-123. doi: 10.5217/ir.2021.00037. Epub 2021 Aug 4.
8
Changes in the Long-term Prognosis of Crohn's Disease between 1986 and 2015: The Population-Based Songpa-Kangdong Inflammatory Bowel Disease Cohort Study.1986 年至 2015 年期间克罗恩病长期预后的变化:基于人群的宋帕-姜洞炎症性肠病队列研究。
Gut Liver. 2022 Mar 15;16(2):216-227. doi: 10.5009/gnl210044.
9
ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections.ACG 临床指南:艰难梭菌感染的预防、诊断和治疗。
Am J Gastroenterol. 2021 Jun 1;116(6):1124-1147. doi: 10.14309/ajg.0000000000001278.
10
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.2020 年炎症性肠病循证临床实践指南。
J Gastroenterol. 2021 Jun;56(6):489-526. doi: 10.1007/s00535-021-01784-1. Epub 2021 Apr 22.